Folate binding protein (FBP) is highly over-expressed in breast, ovarian and endometrial cancers and is the source of immunogenic peptides (E39) that can stimulate cytotoxic T lymphocytes (CTL) to recognize and destroy FBP-expressing cancer cells in the laboratory. The purpose of this study is to test whether a peptide-based vaccine consisting of the E39 peptide mixed with the FDA-approved immunoadjuvant granulocyte macrophage colony-stimulating factor (GM-CSF) is safe and effective at inducing an in vivo peptide-specific immune response. Furthermore, the investigators intend to determine the best dose of the vaccine to utilize to produce this immunity most efficiently. The investigators will determine whether immunity to FBP will prevent clinical recurrence. Additionally, the investigators will compare these results with results from a trial utilizing the E75 peptide (from the HER2/neu protein) in ovarian and endometrial cancer patients in preparation for studying a combination vaccine.

Start Date01 Apr 2012

Sponsor / Collaborator

San Antonio Military Medical Center

100 Clinical Results associated with E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

100 Translational Medicine associated with E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

100 Patents (Medical) associated with E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

317

Literatures (Medical) associated with E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

01 Dec 2024·Poultry Science

Fermented blueberry pomace supplementation improves egg quality, liver synthesis, and ovary antioxidant capacity of laying hens

Article

Author: Azad, Md Abul Kalam ; Kong, Xiangfeng ; Wang, Haoran ; Azad, Md. Abul Kalam ; Cui, Yadong ; Lan, Wei ; Qin, Binghua ; Chen, Ting ; Li, Zhihua

The present study aimed to investigate the effects of dietary fermented blueberry pomace (FBP) supplementation on production performance, egg quality and nutritional value, plasma biochemical parameters, follicle number, reproductive hormones, lipid metabolism, and antioxidant capacity of laying hens during the late laying period. A total of 320 (345-d-old) Yukou Jingfen No. 8 laying hens were randomly divided into 4 groups, with eight replicates per group and 10 hens per replicate. The birds were fed a basal diet (control group) and a basal diet supplemented with 0.25, 0.5, and 1.0% FBP. The trial lasted 56 d. The results showed that FBP (0.25-1.0%) supplementation increased the egg albumen height and Haugh unit compared with the control group on d 14, while 0.5 to 1.0% FBP increased the eggshell thickness compared with the 0.25% FBP group on d 28 of the trial (P < 0.05). The methionine content in egg white was higher (P < 0.05) in the 1.0% FBP group compared with the 0.25% FBP group. The CAT activity in the ovary was increased (P < 0.05) in the FBP groups compared with the control group, while plasma GSH-PX activity was higher (P < 0.05) in the 1.0% FBP group compared with the 0.25% FBP and 0.5% FBP groups. Dietary FBP supplementation up-regulated (P < 0.05) gene expressions related to lipid metabolism in the liver (ACC, FAS, SCD1, and SREBP1) and yolk precursor synthesis (ESR2 and VTG II). Moreover, CYP11A1 expression in the ovary was up-regulated (P < 0.05) in the FBP groups compared with the control group, as well as in the 0.25% FBP group compared with the 1.0% FBP group. In summary, dietary FBP supplementation improved egg quality and nutritional value, ovarian antioxidant capacity, and yolk precursor synthesis, while 1.0% FBP had better effects than 0.25 and 0.5% doses.

01 Nov 2024·Journal of Biotechnology

Engineering Escherichia coli for D-allulose biosynthesis from glycerol

Article

Author: Dong, Zhen-Xing ; Zheng, Hui-Dong ; Fan, Li-Hai ; Zheng, Ling-Jie ; Luo, Xuan ; Guo, Qiang

D-allulose, a naturally occurring monosaccharide, is present in small quantities in nature. It is considered a valuable low-calorie sweetener due to its low absorption in the digestive tract and zero energy for growth. Most of the recent efforts to produce D-allulose have focused on in vitro enzyme catalysis. However, microbial fermentation is emerging as a promising alternative that offers the advantage of combining enzyme manufacturing and product synthesis within a single bioreactor. Here, a novel approach was proposed for the efficient biosynthesis of D-allulose from glycerol using metabolically engineered Escherichia coli. FbaA, Fbp, AlsE, and A6PP were used to construct the D-allulose synthesis pathway. Subsequently, PfkA, PfkB, and Pgi were disrupted to block the entry of the intermediate fructose-6-phosphate (F6P) into the Embden-Meyerhof-Parnas (EMP) and pentose phosphate (PP) pathways. Additionally, GalE and FryA were inactivated to reduce D-allulose consumption by the cells. Finally, a fed-batch fermentation process was implemented to optimize the performance of the cell factory. As a result, the titer of D-allulose reached 7.02 g/L with a maximum yield of 0.287 g/g.

01 Oct 2024·Physiological Reports

Fructose‐1,6‐bisphosphate reverses hypotensive effect caused by L‐kynurenine in Wistar male rats

Article

Author: Becker, Tiago ; Catarina, Anderson Velasque ; Nunes, Fernanda Bordignon ; Branchini, Gisele ; de Oliveira, Jarbas Rodrigues ; Caceres, Rafael Andrade ; Ferreira, Luis Fernando ; Costa, Bruna Pasqualotto ; Fernandes, Renata Streck ; Rigatto, Katya ; Machado, Kleiton Lima De Godoy

AbstractHypotension is one of the main characteristics of the systemic inflammation, basically caused by endothelial dysfunction. Studies have shown that the amino acid L‐kynurenine (KYN) causes vasodilation in mammals, leading to hypotensive shock. In hypotensive shock, when activated by the KYN, the voltage‐gated potassium channel encoded by the family KCNQ (Kv7) gene can cause vasodilation. Fructose‐1,6‐bisphosphate (FBP) it is being considered in studies an anti‐inflammatory, antioxidant, immunomodulator, and a modulator of some ion channels (Ca2+, Na+, and K+). We analyzed the effects of KYN and FBP on mean blood pressure (MBP), systolic and diastolic (DBP) blood pressure, and heart rate variability (HRV) in Wistar rats. Results demonstrated that the administration of KYN significant decreased MBP, DBP, and increased HRV. Importantly, the FBP treatment reversed the KYN effects on MBP, DBP, and HRV. Molecular Docking Simulations suggested that KYN and FBP present a very close estimated free energy of binding and the same position into structure of KCNQ4. Our results did demonstrate that FBP blunted the decrease in BP, provoked by KYN. Results raise new hypotheses for future and studies in the treatment of hypotension resulting from inflammation.

100 Deals associated with E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Phase 2	-	The Henry M. Jackson Foundation	-
Breast Cancer	Phase 2	-	The University of Texas MD Anderson Cancer Center	-
Breast Cancer	Phase 2	-	Galena Biopharma, Inc.	-
Endometrial Carcinoma	Phase 2	-	The Henry M. Jackson Foundation	-
Endometrial Carcinoma	Phase 2	-	The University of Texas MD Anderson Cancer Center	-
Endometrial Carcinoma	Phase 2	-	Galena Biopharma, Inc.	-
Ovarian Cancer	Phase 2	-	The University of Texas MD Anderson Cancer Center	-
Ovarian Cancer	Phase 2	-	The Henry M. Jackson Foundation	-
Breast Cancer	Preclinical	US	Anderson University	-
Endometrial Carcinoma	Preclinical	US	SELLAS Life Sciences Group, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AACR2016	Phase 1	Ovarian Cancer	51	E39’	(ibnlgjegga) = avopyaynrk uqovgshpkb (aifvfqbjtw )	Positive	15 Jul 2016
				E39 + GM-CSF	(ibnlgjegga) = ubuaxeaozw uqovgshpkb (aifvfqbjtw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

E39+GM-CSF vaccine(The University of Texas MD Anderson Cancer Center)

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation